Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Hematopoietic SCT for peripheral T-cell lymphoma

Abstract

Results of conventional chemotherapy for high-risk peripheral T-cell lymphoma (PTCL) are poor compared with those for their aggressive B-cell counterparts. We aim to review the current data on the use of hematopoietic SCT in these patients in both frontline and salvage settings. With respect to autologous SCT (ASCT), conclusions from retrospective studies are that ASCT in the salvage setting is as useful in PTCL as in aggressive B-cell lymphomas and also that consolidation in first complete response of high-risk patients has very good results when compared with conventional chemotherapy (with long-term PFS higher than 50%). From first frontline prospective clinical trials, it appears that ASCT is feasible and has a low TRM (<5%); consolidation in first complete response is associated with a very good outcome; around 25% of patients do not undergo ASCT due mainly to disease progression; new approaches aimed at increasing the number of chemosensitive patients should be found. Furthermore, 25–30% of patients deemed complete responders post transplant still relapse afterward. For all these mainly chemoresistant patients, there is preliminary evidence that allogeneic SCT (Allo-SCT) may produce a plateau in survival curves (with long-term PFS around 50%), which indicates a graft-versus-PTCL effect. For this reason, Allo-SCT procedures are the object of ongoing clinical trials.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Chan JK . Peripheral T-cell and NK-cell neoplasms: an integrated approach to diagnosis. Mod Pathol 1999; 12: 177–199.

    CAS  PubMed  Google Scholar 

  2. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89: 3909–3918.

  3. Melnyk A, Rodriguez A, Pugh WC, Cabannillas F . Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood 1997; 89: 4514–4520.

    CAS  PubMed  Google Scholar 

  4. Rüdiger T, Weisenburger DD, Anderson JR, Armitage JO, Diebold J, MacLennan KA et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 2002; 13: 140–149.

    Article  PubMed  Google Scholar 

  5. AbouYabis AN, Shenoy PJ, Flowers C, Lechowicz MJ . Response and survival rates in patients with peripheral T-cell lymphoma treated with anthracycline-based regimens: a comprehensive meta-analysis. Blood 2007; 110: 3452.

    Google Scholar 

  6. Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM . Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 2004; 15: 1467–1475.

    Article  CAS  PubMed  Google Scholar 

  7. Bierman P, Vose JM, Bociek RG, Loberiza F, Bast M, Weisenburger DD et al. Outcome of limited-stage peripheral T-cell lymphoma: results from the Nebraska Lymphoma Study Group. Blood 2007; 110: 3451.

    Google Scholar 

  8. Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM et al. ALK-negative anaplastic large-cell lymphoma (ALCL) is clinically and immunophenotypically different from both ALK-positive ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008; 111: 5496–5504.

    Article  CAS  PubMed  Google Scholar 

  9. Escalon MP, Liu NS, Yang Y, Hess M, Walker PL, Smith TL et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the MD Anderson Cancer Center experience. Cancer 2005; 103: 2091–2098.

    Article  PubMed  Google Scholar 

  10. Blystad AK, Enblad G, Kvaloy S, Berglund A, Delabie J, Holte H et al. High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant 2001; 27: 711–716.

    Article  CAS  PubMed  Google Scholar 

  11. Caballero MD, Perez-Simon JA, Iriondo A, Lahuerta JJ, Sierra J, Marin J et al. High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group. Ann Oncol 2003; 14: 140–151.

    Article  CAS  PubMed  Google Scholar 

  12. Kewalramani T, Zelenetz AD, Teruya-Feldstein J, Hamlin P, Yahalom J, Horwitz S et al. Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol 2006; 134: 202–207.

    Article  PubMed  Google Scholar 

  13. Feyler S, Prince HM, Pearce R, Towlson K, Nivison-Smith I, Schey S et al. The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transplant 2007; 40: 443–450.

    Article  CAS  PubMed  Google Scholar 

  14. Rodriguez J, Conde E, Gutierrez A, Lahuerta JJ, Arranz R, Sureda A et al. The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma. Haematologica 2007; 92: 1067–1074.

    Article  PubMed  Google Scholar 

  15. Rodriguez J, Munsell M, Yazji S, Hagemeister FB, Younes A, Andersson B et al. Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol 2001; 19: 3766–3770.

    Article  CAS  PubMed  Google Scholar 

  16. Song KW, Mollee P, Keating A, Crump M . Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. Br J Haematol 2003; 120: 978–985.

    Article  PubMed  Google Scholar 

  17. Jantunen E, Wiklund T, Juvonen E, Putkonen M, Lehtinen T, Kuittinen O et al. Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey. Bone Marrow Transplant 2004; 33: 405–410.

    Article  CAS  PubMed  Google Scholar 

  18. Smith SD, Bolwell BJ, Rybicki LA, Brown S, Dean R, Kalaycio M et al. Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen. Bone Marrow Transplant 2007; 40: 239–243.

    Article  CAS  PubMed  Google Scholar 

  19. Rodriguez J, Conde E, Gutierrez A, Arranz R, Leon A, Marin J et al. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol 2007; 18: 652–657.

    Article  CAS  PubMed  Google Scholar 

  20. Rodriguez J, Caballero MD, Gutierrez A, Gandarillas M, Sierra J, Lopez-Guillermo A et al. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience. Haematologica 2003; 88: 1372–1377.

    CAS  PubMed  Google Scholar 

  21. Rodriguez J, Caballero MD, Gutierrez A, Marin J, Lahuerta JJ, Sureda A et al. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. Ann Oncol 2003; 14: 1768–1775.

    Article  CAS  PubMed  Google Scholar 

  22. Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004; 103: 2474–2479.

    Article  CAS  PubMed  Google Scholar 

  23. Rodriguez J, Conde E, Gutierrez A, Arranz R, Gandarillas M, Leon A et al. Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience. Eur J Haematol 2007; 78: 290–296.

    Article  PubMed  Google Scholar 

  24. Kyriakou C, Canals C, Goldstone A, Caballero D, Metzner B, Kobbe G et al. High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008; 26: 218–224.

    CAS  PubMed  Google Scholar 

  25. Corradini P, Tarella C, Zallio F, Dodero A, Zanni M, Valagussa P et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 2006; 20: 1533–1538.

    Article  CAS  PubMed  Google Scholar 

  26. Reimer P, Ruediger T, Weissinger F, Mueller-Hermelink HK, Engert A, Einsele H et al. Different outcome for angioimmunoblastic T-cell lymphoma (AIL) and peripheral T-cell lymphoma unspecified (PTCL-U) following upfront autologous stem cell transplantation. Blood 2006; 108: 5431a.

    Google Scholar 

  27. d’Amore F, Relander T, Lauritzsen G, Jantunen E, Hagberg H, Anderson H et al. Dose-dense induction followed by autologous stem cell transplant (ASCT) as 1st line treatment in peripheral T-cell lymphomas (PTCL)—a Phase II Study of the Nordic Lymphoma Group (NLG). Blood 2006; 108: 401a.

    Article  Google Scholar 

  28. Rodriguez J, Conde E, Gutierrez A, Arranz R, Leon A, Marin J et al. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol 2007; 79: 32–38.

    Article  PubMed  Google Scholar 

  29. Mercadal S, Briones J, Xicoy B, Pedro C, Escoda L, Estany C et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 2008; 19: 958–963.

    Article  CAS  PubMed  Google Scholar 

  30. Reimer P, Schertlin T, Rüdiger T, Geissinger E, Roth S, Kunzmann V et al. Myeloablative radiochemotherapy followed by autologous peripheral blood stem cell transplantation as first-line therapy in peripheral T-cell lymphomas: first results of a prospective multicenter study. Hematol J 2004; 5: 304–311.

    Article  CAS  PubMed  Google Scholar 

  31. Reimer P, Rüdiger T, Einsele H, Geissinger E, Weissinger F, Nerl C et al. Autologous stem cell transplantation (autoSCT) as first-line therapy in peripheral T cell lymphomas (PTCL): results of a prospective multicenter study. J Clin Oncol 2008; 26: 8515.

    Article  Google Scholar 

  32. Sureda A, Arranz R, Iriondo A, Carreras E, Lahuerta JJ, Garcia-Conde J et al. Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Gruppo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group. J Clin Oncol 2001; 19: 1395–1404.

    Article  CAS  PubMed  Google Scholar 

  33. Mercadal S, Lopez-Guillermo A, Briones J, Xicoy B, Pedro C, Escoda L et al. Is there a role for autologous stem-cell transplantation (ASCT) in peripheral T-cell lymphoma (PTCL)? Final results of a prospective phase II study from the GELCAB. Blood 2006; 108: 3070a.

    Google Scholar 

  34. d’Amore F . High-dose therapy and autologous stem cell transplant as first line treatment in peripheral T-cell lymphomas. Ann Oncol 2005; 16: v15–v26.

    Article  Google Scholar 

  35. Corradini P, Dodero A, Zallio F, Caracciolo D, Casini M, Bregni M et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 2004; 22: 2172–2176.

    Article  PubMed  Google Scholar 

  36. Le Gouill S, Milpied N, Buzyn A, De Latour RP, Vernant JP, Mohty M et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol 2008; 26: 2264–2271.

    Article  PubMed  Google Scholar 

  37. Wulf GG, Hasenkamp J, Jung W, Chapuy B, Truemper L, Glass B . Reduced intensity conditioning and allogeneic stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed peripheral T-cell non-Hodgkin's lymphoma. Bone Marrow Transplant 2005; 36: 271–273.

    Article  CAS  PubMed  Google Scholar 

  38. Tanosaki R, Kim S, Yamazaki S, Fukuda T, Mori S, Heike Y et al. A retrospective single institute analysis of 127 lymphoma patients who underwent allogeneic stem cell transplantation: impact on peripheral T-cell lymphoma (PTCL) including ATLL. Blood 2006; 108: 3031.

    Google Scholar 

  39. Zain J, Palmer J, Tsai N, Popplewell L, Nadamanee A, Krishnan A et al. Clinical outcomes of patients with T cell NHL undergoing allogeneic stem cell transplant. Blood 2006; 108: 3026.

    Google Scholar 

  40. O’Leary HM, Savage KJ, Toze CL, Connors JM, Gascoyne RD, Mourad YA et al. Allogeneic stem cell transplantation as treatment for relapsed and high-risk peripheral T-Cell lymphoma. Blood 2007; 110: 3040.

    Google Scholar 

  41. Günther A, Schade H, Humpe A, Gahn B, Claviez A, Schrauder A et al. BEAM-alemtuzumab followed by allogeneic SCT is a feasible and highly efficient treatment strategy in relapsed or refractory T-NHL. Bone Marrow Transplant 2008; 41 (S1): S244.

    Google Scholar 

  42. Hamadani M, Awan FT, Elder P, Lin TS, Porcu P, Blum KA et al. Allogeneic hematopoietic stem cell transplantation for peripheral T cell lymphomas: evidence of graft-versus-T cell lymphoma effect. Biol Blood Marrow Transplant 2008; 14: 480–483.

    Article  PubMed  Google Scholar 

  43. Kim JG, Sohn SK, Chae YS, Kim DH, Baek JH, Lee KB et al. CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas. Cancer Chemother Pharmacol 2006; 58: 35–39.

    Article  PubMed  Google Scholar 

  44. Kurzrock R, Ravandi F . Purine analogues in advanced T-cell lymphoid malignancies. Semin Hematol 2006; 43 (2 Suppl 2): S27–S34.

    Article  CAS  PubMed  Google Scholar 

  45. O’Connor OA, Hamlin PA, Portlock C, Moskowitz CH, Noy A, Straus DJ et al. Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma. Br J Haematol 2007; 139: 425–428.

    Article  PubMed  Google Scholar 

  46. Gallamini A, Zaja F, Patti C, Billio A, Specchia MR, Tucci A et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 2007; 110: 2316–2323.

    Article  CAS  PubMed  Google Scholar 

  47. Foss F . Clinical experience with denileukin diftitox (ONTAK). Semin Oncol 2006; 33 (1 Suppl 3): S11–S16.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J Rodriguez.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gutiérrez, A., Caballero, M., Pérez-Manga, G. et al. Hematopoietic SCT for peripheral T-cell lymphoma. Bone Marrow Transplant 42, 773–781 (2008). https://doi.org/10.1038/bmt.2008.332

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.332

Keywords

This article is cited by

Search

Quick links